uniQurex (QURE) Nearly Quadruples on Stellar Results for Huntington Disease Treatment

We recently published 10 Big Names With Explosive Gains That Investors Can’t Ignore. uniQure NV (NASDAQ:QURE) is one of the companies that soared by double- and triple-digits last week.

uniQure soared by 291 percent week-on-week to climb to a new all-time high as investors cheered the stellar performance of its potential drug treatment for Huntington’s disease.

In Friday’s session, uniQure NV (NASDAQ:QURE) soared to its highest 52-week price of $55.11 before trimming gains to end the day just up by 3.15 percent at $54.31 apiece.

This followed an announcement on the same day that its potential treatment slowed progression of Huntington’s disease by 75 percent after 36 months.

Uniqure NV (NASDAQ:QURE) said the drug candidate, AMT-130, was well-tolerated and that no adverse effects have been observed since 2022.

The company said that the Food and Drug Administration (FDA) has granted AMT-130 Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations.

“We are incredibly excited about these topline results and what they may represent for individuals and families affected by Huntington’s disease,” said Uniqure NV (NASDAQ:QURE) Chief Medical Officer Walid Abi-Saab.

“These findings reinforce our conviction that AMT-130 has the potential to fundamentally transform the treatment landscape for Huntington’s disease, while also providing important evidence supporting one-time, precision-delivered gene therapies for the treatment of neurological disorders,” he noted.

While we acknowledge the potential of QURE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.